검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 3BNC117 |
Overview Company | Rigshospitalet, Denmark |
Overview Modality | ANTIBODY |
Overview Target | Human Immunodeficiency Virus (HIV) |
Overview Indication | Human Immunodeficiency Virus (HIV) |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | biomarker threshold of >200, which was recently identified as a surrogate endpoint for evaluation of the p |
PK/PD Species | NHP, Mouse |
PK/PD Animal (cat.) | Human, Mouse, NHP |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | NHP, Mouse |
Toxicology Animal (cat.) | Human, Mouse, NHP |
Toxicology Major finding | Once yearly cell-based therapy for sustained and dose tunable delivery of monoclonal antibodies.. Over 200 monoclonal antibodies (mAbs) are approved for clinical use, yet their therapeutic potential is constrained by dependence on repeated injections or infusions that drive non-adherence, limit access in low-resource settings, and generate peak-trough pharmacokinetics linked to adverse effects and… |
Clinical Data Tier / Score | A · 29 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 3BNC117 |
Overview Company | Rigshospitalet, Denmark |
Overview Modality | ANTIBODY |
Overview Target | Human Immunodeficiency Virus (HIV) |
Overview Indication | Human Immunodeficiency Virus (HIV) |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | biomarker threshold of >200, which was recently identified as a surrogate endpoint for evaluation of the p |
PK/PD Species | NHP, Mouse |
PK/PD Animal (cat.) | Human, Mouse, NHP |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | NHP, Mouse |
Toxicology Animal (cat.) | Human, Mouse, NHP |
Toxicology Major finding | Once yearly cell-based therapy for sustained and dose tunable delivery of monoclonal antibodies.. Over 200 monoclonal antibodies (mAbs) are approved for clinical use, yet their therapeutic potential is constrained by dependence on repeated injections or infusions that drive non-adherence, limit access in low-resource settings, and generate peak-trough pharmacokinetics linked to adverse effects and… |
Clinical Data Tier / Score | A · 29 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교